Novel Afro-Caribbean Prostate Cancer Model Reveals Ancestry-Specific Drug Vulnerabilities with Therapeutic Implications for Black Patients Open Access
Simone Badal Bor-Jang Hwang Ashlianne Nelson Kristoff Frank Tanisha Maitre Magdalene Nwokocha Rory Thompson Belinda Morison Rajini Haraksingh Valerie Odero-Marah Camille Ragin
In the age of targeted therapies, scientists are developing increasingly sophisticated treatments that exploit the unique vulnerabilities of cancer cells. But what if the models used to develop these therapies fail to represent the patients they’re designed to treat?
A 2025 study led by Jamaican scientist Dr. Simone Badal investigated this problem by comparing prostate cancer cell lines derived from Black and White patients. Using drug screening and RNA sequencing (a technique used to measure which genes are active in a cell), researchers examined how different cancer models responded to five anticancer medications.
The results revealed striking differences. Enzalutamide, a prostate cancer treatment that blocks androgen receptor signalling, was approximately 3–5 times less potent in Black-derived cell lines than White-derived models. Conversely, abiraterone was 4.6–13.1 times more potent in a newly developed Afro-Caribbean cell line than in the other models tested.
Further analysis revealed differences in gene expression, including reduced expression of TNFRSF14, a gene involved in immune signalling, suggesting potential molecular contributors to these varying drug responses.
Although these findings require validation in patients, they expose a critical limitation in preclinical research: the models we use may not capture the biological diversity of the populations we aim to treat.
We are developing medicines with the potential to radically improve patients’ lives. But without diversity in the science behind their development, we risk overlooking the very vulnerabilities that could make these treatments effective.